Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer

M. P. Herman, R. S. Svatek, Yair Lotan, P. I. Karakiewizc, S. F. Shariat

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Bladder cancer has a very high frequency of recurrence and therefore requires lifelong surveillance, traditionally consisting of serial cystoscopy and cytology. These tests are both invasive and expensive, with considerable inter-user and inter-institutional variability. In addition, the sensitivity of cytology in detecting low-grade tumors is low. Therefore, there has been active investigation into urinary biomarkers that can either supplement or supplant these tests. At this point there are only six urine-based tests that are FDA-approved in bladder cancer surveillance, but a wide variety of other biomarkers are being studied. In this review, we examine the natural history of bladder cancer as well as the rationale and performance of an ideal urinary biomarker. The authors describe the FDA-approved biomarkers such as Bladder Tumor Antigen, ImmunoCyt, Nuclear Matrix Protein-22, and Fluorescent In Situ Hybridization, as well as the most promising investigational tests (i.e., Urinary bladder cancer test, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, and telomerase). The biological foundation, methodologies, and diagnostic performance of the biomarkers are discussed. The characteristics of the biomarkers are compared to urine cytology. At this time, urine biomarkers are utilized in a variety of clinical situations but their role is not well defined. The goal of identifying an optimal marker that will replace cystoscopy and/or cytology is still ongoing.

Original languageEnglish (US)
Pages (from-to)217-235
Number of pages19
JournalMinerva Urologica e Nefrologica
Volume60
Issue number4
StatePublished - Dec 2008

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Urine
Cell Biology
Cystoscopy
CD15 Antigens
Hyaluronoglucosaminidase
Telomerase
Neoplasm Antigens
Hyaluronic Acid
Fluorescence In Situ Hybridization
Microsatellite Repeats
Recurrence
Neoplasms

Keywords

  • Biological markers
  • Carcinoma, transitional cell
  • Cystoscopy
  • Prognosis
  • Urinary bladder neoplasms

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. / Herman, M. P.; Svatek, R. S.; Lotan, Yair; Karakiewizc, P. I.; Shariat, S. F.

In: Minerva Urologica e Nefrologica, Vol. 60, No. 4, 12.2008, p. 217-235.

Research output: Contribution to journalArticle

Herman, M. P. ; Svatek, R. S. ; Lotan, Yair ; Karakiewizc, P. I. ; Shariat, S. F. / Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. In: Minerva Urologica e Nefrologica. 2008 ; Vol. 60, No. 4. pp. 217-235.
@article{1e879e8379b6446099033803d0a527aa,
title = "Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer",
abstract = "Bladder cancer has a very high frequency of recurrence and therefore requires lifelong surveillance, traditionally consisting of serial cystoscopy and cytology. These tests are both invasive and expensive, with considerable inter-user and inter-institutional variability. In addition, the sensitivity of cytology in detecting low-grade tumors is low. Therefore, there has been active investigation into urinary biomarkers that can either supplement or supplant these tests. At this point there are only six urine-based tests that are FDA-approved in bladder cancer surveillance, but a wide variety of other biomarkers are being studied. In this review, we examine the natural history of bladder cancer as well as the rationale and performance of an ideal urinary biomarker. The authors describe the FDA-approved biomarkers such as Bladder Tumor Antigen, ImmunoCyt, Nuclear Matrix Protein-22, and Fluorescent In Situ Hybridization, as well as the most promising investigational tests (i.e., Urinary bladder cancer test, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, and telomerase). The biological foundation, methodologies, and diagnostic performance of the biomarkers are discussed. The characteristics of the biomarkers are compared to urine cytology. At this time, urine biomarkers are utilized in a variety of clinical situations but their role is not well defined. The goal of identifying an optimal marker that will replace cystoscopy and/or cytology is still ongoing.",
keywords = "Biological markers, Carcinoma, transitional cell, Cystoscopy, Prognosis, Urinary bladder neoplasms",
author = "Herman, {M. P.} and Svatek, {R. S.} and Yair Lotan and Karakiewizc, {P. I.} and Shariat, {S. F.}",
year = "2008",
month = "12",
language = "English (US)",
volume = "60",
pages = "217--235",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer

AU - Herman, M. P.

AU - Svatek, R. S.

AU - Lotan, Yair

AU - Karakiewizc, P. I.

AU - Shariat, S. F.

PY - 2008/12

Y1 - 2008/12

N2 - Bladder cancer has a very high frequency of recurrence and therefore requires lifelong surveillance, traditionally consisting of serial cystoscopy and cytology. These tests are both invasive and expensive, with considerable inter-user and inter-institutional variability. In addition, the sensitivity of cytology in detecting low-grade tumors is low. Therefore, there has been active investigation into urinary biomarkers that can either supplement or supplant these tests. At this point there are only six urine-based tests that are FDA-approved in bladder cancer surveillance, but a wide variety of other biomarkers are being studied. In this review, we examine the natural history of bladder cancer as well as the rationale and performance of an ideal urinary biomarker. The authors describe the FDA-approved biomarkers such as Bladder Tumor Antigen, ImmunoCyt, Nuclear Matrix Protein-22, and Fluorescent In Situ Hybridization, as well as the most promising investigational tests (i.e., Urinary bladder cancer test, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, and telomerase). The biological foundation, methodologies, and diagnostic performance of the biomarkers are discussed. The characteristics of the biomarkers are compared to urine cytology. At this time, urine biomarkers are utilized in a variety of clinical situations but their role is not well defined. The goal of identifying an optimal marker that will replace cystoscopy and/or cytology is still ongoing.

AB - Bladder cancer has a very high frequency of recurrence and therefore requires lifelong surveillance, traditionally consisting of serial cystoscopy and cytology. These tests are both invasive and expensive, with considerable inter-user and inter-institutional variability. In addition, the sensitivity of cytology in detecting low-grade tumors is low. Therefore, there has been active investigation into urinary biomarkers that can either supplement or supplant these tests. At this point there are only six urine-based tests that are FDA-approved in bladder cancer surveillance, but a wide variety of other biomarkers are being studied. In this review, we examine the natural history of bladder cancer as well as the rationale and performance of an ideal urinary biomarker. The authors describe the FDA-approved biomarkers such as Bladder Tumor Antigen, ImmunoCyt, Nuclear Matrix Protein-22, and Fluorescent In Situ Hybridization, as well as the most promising investigational tests (i.e., Urinary bladder cancer test, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, and telomerase). The biological foundation, methodologies, and diagnostic performance of the biomarkers are discussed. The characteristics of the biomarkers are compared to urine cytology. At this time, urine biomarkers are utilized in a variety of clinical situations but their role is not well defined. The goal of identifying an optimal marker that will replace cystoscopy and/or cytology is still ongoing.

KW - Biological markers

KW - Carcinoma, transitional cell

KW - Cystoscopy

KW - Prognosis

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=57649126208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649126208&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 217

EP - 235

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 4

ER -